It is our mission to enhance the practice of rehabilitation and continuing medical care through research and education. This is why we are active in conducting clinical trials and evaluating new treatments, technologies, and finding new solutions. We are uniquely skilled to conduct clinical trials in the areas of, neuromuscular care including Amyotrophic Lateral Sclerosis (ALS) and Muscular Dystrophy, as well as Parkinson’s Disease. As a participant in one of our clinical trials, you have the opportunity to enhance your care and ensure that future generations have access to the highest level of care.
Six Active Research Projects
- HEALEY ALS PLATFORM – A Platform Trial in which multiple interventions are tested and evaluated simultaneously for the Treatment of ALS. Placebo / Control Phase – 25% receive placebo vs 75% receive active drug, then followed by active treatment.
- ALL ALS East Biorepository – A large biomarker study that follows 3 groups of patients:
- Assess (2 groups): Patients with ALS and patients without ALS (controls)
- Prevent: Family members of patients with known genetic cause of ALS
- Pridopidine Expanded Access Protocol (EAP) 2 – Oral Pridopidine treatment for patients diagnosed with ALS that do not qualify for other clinical trials.
- Clene Nanomedicine CNM-Au8 – A Second Intermediate Expanded Access Protocol (EAP) for ALS with CNM-Au8
- Ibudilast EAP – A compassionate use EAP of MN-166 for patients with ALS
- Usnoflast-Phase 2b – ALS patients treated with oral USNO.24.002